Identifying founder mutations would enable us to examine specific loci in the screening of high-risk subpopulations for inherited breast and ovarian cancer without performing a full sequence analysis of BRCA1 and BRCA2. Founder mutations have previously been described in an Ashkenazi Jewish population in which 3% of individuals carried BRCA1 c.185delAG, BRCA1 c.5382insC, or BRCA2 c.6174delT mutations (Ferla et al. The gene discussed is BRCA2; the disease is ovarian carcinoma.